Sage Therapeutics to Participate in Goldman Sachs Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Sage Therapeutics SAGE, a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer of Sage, will participate in a fireside chat at the Goldman Sachs Healthcare CEOs Unscripted conference on Thursday, January 5th, 2017 at 2:30 p.m. ET in Boston, MA.

A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.

About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161229005239/en/